lifestyle.thedishh.com

Author: Insilico Medicine

Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial

March 6, 2026
Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery

March 3, 2026
Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies

February 25, 2026
AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases

February 10, 2026
Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology

February 7, 2026
Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications

February 7, 2026
Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501

February 7, 2026
Up to 31.3% Body Weight Loss, Insilico Medicine Nominates AI-Powered GIPR Antagonist ISM0676 as Preclinical Candidate, Showing Synergistic Efficacy in Combination Therapy

January 29, 2026
Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor

January 23, 2026
Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines

January 23, 2026